]>
IRCT2017073135415N1 IRCT 2017-09-17 Vice chancellor for research, Qom University of Medical Sciences Assesment of "Dawa al-Blaghm" on liver enzymes in patients with fatty liver Evaluation of the effect of Dva’-Albalgham ,on serum levels of liver enzymes in patients with NAFLD. 2017-08-21 anticipated 100 Complete https://irct.ir/trial/26767 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: By using the available sampling method, individuals with entry and failure criteria will be included in the study, then treatments will be assigned based on random blocks of four. The blocks and its size and code of cure will be provided by a counselor to a person other than the medical, who measures the response of the patients. Blocks will be randomly selected. According to the estimated number of samples, 25 blocks of volume 4 will be used to select random blocks of dice throwing or Proc PLAN in SAS 9.2 software. Which is based on the treatments provided. In this way, the choice of treatment type, block selection and sequence of individuals in each block will also be random. N/A Fatty liver desease. Intervention 1: The case group receives Dava Al-balgham tablets two pills with each meal, for three months. Intervention 2: The control group receives cellulose tablets in two tablets each serving for three months.
public Hossein Moradi
Faculty of Traditional Iranian Medicine, Third Floor, Faculty of Dentistry,Saheli St. Qom.Iran.
Qom Iran (Islamic Republic of) +98 25 3770 7843 moradi.medicine@yahoo.com Faculty of Traditional Iranian Medicine Qom scientific Hossein moradi
Faculty of Traditional Iranian Medicine, Third Floor, Faculty of Dentistry,Saheli St. Qom.Iran.
Qom Iran (Islamic Republic of) +98 25 3770 7843 moradi.medicine@yahoo.com Faculty of Medicine, Qom University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: 1- Non-Alcohol-Fatty Liver Detection (NAFLD-Based Ultrasonography) 2- Serum Liver Enzyme Levels above Normal 3- Age between 18 and 65 years. 4- Fill in the consent form for participation in the plan. Exclusion criteria: 1. Patient's lack of consent to continue participating in the project. 2. Any allergy to the drug. 3. The occurrence of any new liver disease that requires the use of specific liver medicines. 4. Pregnancy. 17 years 64 years Both k76.0 Nonalcoholic fatty liver disease (NAFLD) Treatment - Drugs Treatment - Drugs The case group receives Dava Al-balgham tablets two pills with each meal, for three months. The control group receives cellulose tablets in two tablets each serving for three months. Ast. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer. Alt. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer. Alkp. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer. Crt. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer. BUN. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer. PT. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer. PTT. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer. INR. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer. Level of quality of life. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Questionnaire 36 questions. BMI. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Weight/(height(meter))2 Kg/m2. WHR. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Waist to hip circumference Cm/cm. Blood presure. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Mercury pressure meter mmHg. Vice chancellor for research, Qom University of Medical Sciences Approved 2017-07-04 Ethics committee of Qom University of Medical Sciences University of Medical Sciences, Saheli street, Qom, Iran Qom Iran (Islamic Republic of)